Serum Receptor Activator of Nuclear Factor-κ B Ligand, Osteoprotegrin, and Intact Parathyroid Hormone in Hemodialysis and Renal Transplant Patients

被引:6
|
作者
Rashtchizadeh, Nadereh [2 ]
Ghorbanihaghjo, Amir [1 ]
Argani, Hassan [2 ]
Meimand, Saeed Mahmoudi [2 ]
Safa, Javid [2 ]
Vatankhahan, Hamidreza [2 ]
Shahidi, Maryam [2 ]
机构
[1] Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz 51664, Iran
[2] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz 51664, Iran
关键词
Hemodialysis; Kidney transplanted patients; Osteoprotegrin; Serum receptor activator of nuclear factor-kappa B ligand; VASCULAR CALCIFICATION; BONE-RESORPTION; DISEASE; OSTEOCLASTOGENESIS; ATHEROSCLEROSIS; EXPRESSION; MARKERS; RATS; OPG;
D O I
10.1111/j.1744-9987.2012.01097.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Serum receptor activator of nuclear factor-? B ligand and osteoprotegrin are mediated to vascular calcification in the general population. Our knowledge is very sparse in hemodialysis and renal transplant patients. Receptor activator of nuclear factor-? B ligand, osteoprotegrin, intact parathyroid hormone, calcium, and phosphorus were measured in blood samples of 45 hemodialysis and 45 age-matched renal transplant patients. Osteoprotegrin (P = 0.001) and intact parathyroid hormone (P = 0.001) levels in the hemodialysis patients were higher than the renal transplant recipients. Osteoprotegrin had positive correlation with duration of dialysis and age in the hemodialysis (r = 0.88, P = 0.001 and r = 0.34, P = 0.02, respectively) and renal transplant patients (r = 0.92, P = 0.001 and r = 0.46, P = 0.001, respectively). Hemodialysis patients have higher osteoprotegrin levels than the renal transplant recipients. It may act as a protective factor for renal osteodystrophy or only as a secondary phenomenon of advanced renal failure.
引用
收藏
页码:600 / 604
页数:5
相关论文
共 50 条
  • [41] Roles of receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin in periodontal health and disease
    Nagasawa, Toshiyuki
    Kiji, Makoto
    Yashiro, Reiko
    Hormdee, Doosadee
    He, Lu
    Kunze, Melanie
    Suda, Tomonari
    Koshy, Geena
    Kobayashi, Hiroaki
    Oda, Shigeru
    Nitta, Hiroshi
    Ishikawa, Isao
    PERIODONTOLOGY 2000, 2007, 43 : 65 - 84
  • [42] The role of receptor activator of nuclear factor-κB (RANK)/RANK ligand/osteoprotegerin:: Clinical implications
    Vega, Damaris
    Maalouf, Naim M.
    Sakhaee, Khashayar
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (12): : 4514 - 4521
  • [43] Targeting the receptor activator of nuclear factor-κB (RANK) ligand in prostate cancer bone metastases
    Saad, Fred
    Markus, Richard
    Goessl, Carsten
    BJU INTERNATIONAL, 2008, 101 (09) : 1071 - 1075
  • [44] Receptor activator of nuclear factor-κB ligand (RANKL) as a novel prognostic marker in prostate carcinoma
    Perez-Martinez, Francisco C.
    Alonso, Veronica
    Sarasa, Jose L.
    Manzarbeitia, Felix
    Vela-Navarrete, Remigio
    Calahorra, Francisco J.
    Esbrit, Pedro
    HISTOLOGY AND HISTOPATHOLOGY, 2008, 23 (06) : 709 - 715
  • [45] The role of serum osteoprotegerin and receptor–activator of nuclear factor-κB ligand in metabolic bone disease of women after obesity surgery
    José A. Balsa
    Christian Lafuente
    Jesús M. Gómez-Martín
    Julio Galindo
    Roberto Peromingo
    Francisca García-Moreno
    Gloria Rodriguez-Velasco
    Javier Martínez-Botas
    Diego Gómez-Coronado
    Héctor F. Escobar-Morreale
    José I. Botella-Carretero
    Journal of Bone and Mineral Metabolism, 2016, 34 : 655 - 661
  • [46] Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-κB ligand levels in women with established osteoporosis treated with teriparatide
    Anastasilakis, Athanasios D.
    Goulis, Dimirtios G.
    Polyzos, Stergios A.
    Gerou, Spiridon
    Pavlidou, Vasiliki
    Koukoulis, George
    Avramidis, Avraam
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 158 (03) : 411 - 415
  • [47] STUDY OF SERUM OSTEOPROTEGERIN AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA-B LIGAND IN PATIENTS WITH RHEUMATIC DISEASES
    Geneva-Popova, Mariela
    Popova, Stanislava
    JOURNAL OF IMAB, 2021, 27 (04): : 4170 - 4177
  • [48] Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-κB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas
    Kumamoto, H
    Ooya, K
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2004, 33 (01) : 46 - 52
  • [49] Potential pathogenic role of soluble receptor activator of nuclear factor-κB ligand and osteoprotegerin in patients with pulmonary arterial hypertension
    Jasiewicz, Malgorzata
    Knapp, Malgorzata
    Waszkiewicz, Ewa
    Musial, Wlodzimierz J.
    Kaminski, Karol A.
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2014, 124 (11): : 579 - 586
  • [50] Toxicities Following Treatment with Bisphosphonates and Receptor Activator of Nuclear Factor-κB Ligand Inhibitors in Patients with Advanced Prostate Cancer
    Gartrell, Benjamin A.
    Coleman, Robert E.
    Fizazi, Karim
    Miller, Kurt
    Saad, Fred
    Sternberg, Cora N.
    Galsky, Matthew D.
    EUROPEAN UROLOGY, 2014, 65 (02) : 278 - 286